Pfizer Fair value hedge adjustments on discontinued hedges decreased by 2.2% to $803.00M in Q1 2026 compared to the prior quarter.
Changes reflect the legacy impact of past hedging decisions on current liability valuations.
Cumulative adjustments made to the carrying value of liabilities that were previously part of a fair value hedge relatio...
Specific to firms with complex debt and hedging structures; peers report this in debt or hedge accounting disclosures.
other_hedged_liability_discontinued_fair_value_hedge_cum_a80bfa| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $821.00M | $803.00M |
| QoQ Change | — | -2.2% |